MyBlueDotsMeiji Seika Pharma Invests in MPM BioImpact’s New Technologies and Virology Strategy MyBlueDots5 months ago01 mins TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma invests in MPM BioImpact’s new technology and virology strategy to expand early-stage opportunities and enhance the global network. Go to Source Author: Post navigation Previous: Amylyx Pharmaceuticals Announces Proposed Public Offering of Common StockNext: Yagi & Co., Ltd.: New Material “LAVATECH” Containing Lava from Mt. Fuji to Be Exhibited at Heimtextil 2025
‘Master control switch’ protein that heightens neurodegenerative disease offers new treatment target MyBlueDots2 days ago 0
New findings reveal how the heart is organized from the earliest stages of embryonic development MyBlueDots2 days ago 0
Scholastic performance is a key concern for young cancer patients, study finds MyBlueDots2 days ago 0